BEQALZI™ (sonrotoclax) is a BCL-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, ...

Bank of America Global Healthcare Conference 2026 May 13, 2026 7:35 PM EDTCompany ParticipantsAnuj Gaggar - Chief ...

Accelerated approval covers post–BTK inhibitor relapsed/refractory MCL, making sonrotoclax the only BCL2 inhibitor specifically approved for this indication. Independent Lugano-assessed efficacy in ...

C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026C-FORWARD ...

A novel approach using a lysosomal enzyme to prevent and reverse amyloid accumulation inside as well as outside neurons, with greater potency, ...

INDIGO Biosciences today announced the launch of its Transrepression Assay Services, expanding the company’s cell-based reporter assay capabilities for drug discovery teams studying pathway cross-talk ...

Medications are designed to treat diseased tissues while sparing healthy ones, often by attaching the drug to something that helps guide it directly to its target. But drugs also need time to work, ...

Ligand-based drug design combines AI and QSAR modeling to prioritize drug candidates, minimizing preclinical failures and ...

Regulatory Engagement -- Codexis is preparing a briefing for its next FDA interaction as part of the Emerging Technologies ...

Mantle cell lymphoma is a rare, aggressive form of non-Hodgkin lymphoma that affects roughly 3,300 new patients annually in the United States. ・Continued approval will depend on confirmatory trials, ...

Connecticut lawmakers have sent the governor a bill to expand a pilot program that’s meant to explore the therapeutic ...

MIAMI, May 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic ...